Renub

    USA & Canada Cervical Cancer Diagnostic Market, Patients by Test Type (Pap Smear, HPV DNA), in North America

    Excel: 4 Hours
    PDF: 4 Hours
    Jul 2018
    Pages: 67

    Get Free Customization in This Report 

    Cervical cancer is the fourth most common cancer prevailing in women and the seventh in terms of overall cancer incidences. North America Cervical Cancer Screening Market is projected to reach US$ 100 Million by the year 2024. Cervical cancer affects the lower part of the uterus (womb). Cervical cancer generally occurs in women over 30 years. It is mostly caused by the Human papillomavirus (HPV) virus. 

    Increasing cervical cancer prevalence rate is one of the key factors that drive the cervical cancer screening market. Rapidly increasing female population, growing incidence of HPV infections and increasing awareness about cervical cancer screening programs is also expected to drive the cervical cancer screening market in the near future. 
     

    Request a free sample copy of the report: https://www.renub.com/contactus.php


    Renub Research report titled USA & Canada Cervical Cancer Diagnostic Market, Patients by Test Type (Pap Smear, HPV DNA), in North America” provides a complete analysis of North America Cervical Cancer Screening Market. The report provides a complete analysis of North America Cervical Cancer Test Market, Screened Population & Mortality.


    By Test Types – Pap smear Screening Tests is gaining popularity in North America

    The report studies the market and population of the following cervical cancer screening tests: Pap smear Tests and HPV DNA Tests. Pap smear and HPV DNA tests are more popular with the developed countries such as United States.

    canada-united-states-cervical-cancer-screening-market-and-patients-by-test-type-pap-smear-hpv-dna

    By Country – United State has bright future in Cervical Cancer Screening Market in near future

    The report studies the market/screened population of two big North America’s country (United State and Canada) which provides a complete country-wise analysis of North America Cervical Cancer Screening Market, Population and Mortality.

     

    Client can purchase this report in sections through Purchase by Chapter Tab given above

     

    Cervical Cancer Diagnostic Market & Population

    •    Pap Smear Tests Market 
    •    HPV DNA Tests Market 


    Cervical Cancer Mortality Population 

    •    United State 
    •    Canada

    1.    Executive Summary

    2.    North America Cervical Cancer Test (Screening) Analysis

    2.1    North America Cervical Cancer Test Population

    2.1.1    Pap Smear Test Population
    2.1.2    HPV DNA Test Population

    2.2    North America Cervical Cancer Test (Screening) Market

    2.2.1    Pap Smear Test Market
    2.2.2    HPV DNA Test Market

    3.    Market & Population Share – By Countries

    3.1    Population Share – By Countries

    3.1.1    Pap Smear Population
    3.1.2    HPV DNA Population

    3.2    Market Share – By Countries

    3.2.1    Pap Smear Test Market
    3.2.2    HPV DNA Test Market

    4.    United States – Cervical Cancer Test Analysis

    4.1    Population – Cervical Cancer Test (Screening)

    4.1.1    Pap smear Test Population
    4.1.2    HPV DNA Test Population

    4.2    United States Cervical Cancer Mortality

    4.3    Market – Cervical Cancer Test (Screening)

    4.3.1    Pap Smear Test Market
    4.3.2    HPV DNA Test Market

    5.    Canada – Cervical Cancer Test Analysis

    5.1    Population – Cervical Cancer Test (Screening)

    5.1.1    Pap Smear Test Population
    5.1.2    HPV DNA Test Population

    5.2    Canada Cervical Cancer Mortality

    5.3    Market – Cervical Cancer Test (Screening)

    5.3.1    Pap Smear Test Market
    5.3.2    HPV DNA Test Market

    6.    Growth Drivers

    6.1    High Prevalence of HPV Infected Patients
    6.2    Worldwide Rising Incidence of Teenage Sexual Cases

    7.    Challenges

    7.1    Introduction of HPV Vaccination Programs Worldwide  


     

    List of Figures:

    Figure 2‑1: North America – Cervical Cancer Test Population (Million), 2011 – 2017
    Figure 2‑2: North America – Forecast for Cervical Cancer Test Population (Million), 2018 – 2024
    Figure 2‑3: North America – Cervical Cancer Pap smear Test Population (Million), 2011 – 2017
    Figure 2‑4: North America – Forecast for Cervical Cancer Pap smear Test Population (Million), 2018 – 2024
    Figure 2‑5: North America – Cervical Cancer HPV DNA Test Population (Million), 2011 – 2017
    Figure 2‑6: North America – Forecast for Cervical Cancer HPV DNA Test Population (Million), 2018 – 2024
    Figure 2‑7: North America – Cervical Cancer Test Market (Million US$), 2011 – 2017
    Figure 2‑8: North America – Forecast for Cervical Cancer Test Market (Million US$), 2018 – 2024
    Figure 2‑9: North America – Cervical Cancer Pap Smear Test Market (Million US$), 2011 – 2017
    Figure 2‑10: North America – Forecast for Cervical Cancer Pap Smear Test Market (Million US$), 2018 – 2024
    Figure 2‑11: North America – Cervical Cancer HPV DNA Test Market (Million US$), 2011 – 2017
    Figure 2‑12: North America – Forecast for Cervical Cancer HPV DNA Test Market (Million US$), 2018 – 2024

    Figure 3‑1: North America – Cervical Cancer Test Population Share (%), 2011 – 2017
    Figure 3‑2: North America – Forecast for Cervical Cancer Test Population Share (%), 2018 – 2024
    Figure 3‑3: North America – Cervical Cancer Pap smear Test Population Share (%), 2011 – 2017
    Figure 3‑4: North America – Forecast for Cervical Cancer Pap smear Test Population Share (%), 2018 – 2024
    Figure 3‑5: North America – Cervical Cancer HPV DNA Test Population Share (%), 2011 – 2017
    Figure 3‑6: North America – Forecast for Cervical Cancer HPV DNA Test Population Share (%), 2018 – 2024
    Figure 3‑7: North America – Cervical Cancer Test Market Share (%), 2011 – 2017
    Figure 3‑8: North America – Forecast for Cervical Cancer Test Market Share (%), 2018 – 2024
    Figure 3‑9: North America – Cervical Cancer Pap smear Test Market Share (%), 2011 – 2017
    Figure 3‑10: North America – Forecast for Cervical Cancer Pap smear Test Market Share (%), 2018 – 2024
    Figure 3‑11: North America – Cervical Cancer HPV DNA Test Market Share (%), 2011 – 2017
    Figure 3‑12: North America – Forecast for Cervical Cancer HPV DNA Test Market Share (%), 2018 – 2024

    Figure 4‑1: United States – Cervical Cancer Test Population (Thousand), 2011 – 2017
    Figure 4‑2: United States – Forecast for Cervical Cancer Test Population (Thousand), 2018 – 2024
    Figure 4‑3: United States – Cervical Cancer Pap Smear Test Population (Thousand), 2011 – 2017
    Figure 4‑4: United States – Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2018 – 2024
    Figure 4‑5: United States – Cervical Cancer HPV DNA Test Population (Thousand), 2011 – 2017
    Figure 4‑6: United States – Forecast for Cervical Cancer HPV DNA Test Population (Thousand), 2018 – 2024
    Figure 4‑7: United States – Cervical Cancer Mortality (Number), 2011 – 2017
    Figure 4‑8: United States – Cervical Cancer Test Market (Million US$), 2011 – 2017
    Figure 4‑9: United States – Forecast for Cervical Cancer Test Market (Million US$), 2018 – 2024
    Figure 4‑10: United States – Pap smear Test Market (Million US$), 2011 – 2017
    Figure 4‑11: United States – Forecast for Pap Smear Test Market (Million US$), 2018 – 2024
    Figure 4‑12: United States – HPV DNA Test Market (Million US$), 2011 – 2017
    Figure 4‑13: United States – Forecast for HPV DNA Test Market (Million US$), 2018 – 2024

    Figure 5‑1: Canada – Cervical Cancer Test Population (Thousand), 2011 – 2017
    Figure 5‑2: Canada – Forecast for Cervical Cancer Test Population (Thousand), 2018 – 2024
    Figure 5‑3: Canada – Cervical Cancer Pap Smear Test Population (Thousand), 2011 – 2017
    Figure 5‑4: Canada – Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2018 – 2024
    Figure 5‑5: Canada – Cervical Cancer HPV DNA Test Population (Thousand), 2011 – 2017
    Figure 5‑6: Canada – Forecast for Cervical Cancer HPV DNA Test Population (Thousand), 2018 – 2024
    Figure 5‑7: Canada – Cervical Cancer Mortality (Number), 2011 – 2017
    Figure 5‑8: Canada – Cervical Cancer Test Market (Million US$), 2011 – 2017
    Figure 5‑9: Canada – Forecast for Cervical Cancer Test Market (Million US$), 2018 – 2024
    Figure 5‑10: Canada – Pap Smear Test Market (Million US$), 2011 – 2017
    Figure 5‑11: Canada – Forecast for Pap Smear Test Market (Million US$), 2018 – 2024
    Figure 5‑12: Canada – HPV DNA Test Market (Million US$), 2011 – 2017
    Figure 5‑13: Canada – Forecast for HPV DNA Test Market (Million US$), 2018 – 2024

     

    List of Tables:

    Table 6‑1: Worldwide – Prevalence of HPV 16/18 in Women with Normal Cervical Cytology (Percent), 2014 - 2015
    Table 6‑2: Worldwide – Prevalence (Percent) of Young Women (15–44 Years) who Have Sex before the Age of 15 Years, 1994 – 2006

    • Description
      Price
    • Chapter 1 & 2     Pages : 13
      $400
    • Chapter 3     Pages : 10
      $400
    • Chapter 4     Pages : 12
      $350
    • Chapter 5     Pages : 11
      $350
    • Chapter 6 & 7     Pages : 6
      $300

    Related Reports